BIOATLA, INC. Stock-Based Compensation
BIOATLA, INC. (BCAB) reported Stock-Based Compensation of $619.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- BIOATLA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $619.00K, a 55.05% decline year-over-year.
- BIOATLA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $956.00K, a 41.88% decline year-over-year.
- BIOATLA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.12M, a 42.00% decline year-over-year.
- BIOATLA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.29M, a 41.11% decline year-over-year.
- BIOATLA, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $5.43M, a 39.09% decline from fiscal 2024.
- BIOATLA, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $8.92M, a 34.13% decline from fiscal 2023.
- BIOATLA, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $13.54M, a 7.00% decline from fiscal 2022.
- BIOATLA, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $14.56M, a 42.02% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $619.00K 10-Q · filed 2026-08-13 | $1.57M 10-Q · filed 2026-08-13 | $2.69M derived: sum of 3 quarters · filed 2026-08-13 | $3.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $956.00K 10-Q · filed 2026-05-15 | $2.08M derived: sum of 2 quarters · filed 2026-05-15 | $3.37M derived: sum of 3 quarters · filed 2026-05-15 | $4.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.41M derived: sum of 2 quarters · filed 2026-03-31 | $3.79M derived: sum of 3 quarters · filed 2026-08-13 | $5.43M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.29M 10-Q · filed 2025-11-13 | $2.67M derived: sum of 2 quarters · filed 2026-08-13 | $4.31M 10-Q · filed 2025-11-13 | $6.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.38M 10-Q · filed 2026-08-13 | $3.02M 10-Q · filed 2026-08-13 | $4.95M derived: sum of 3 quarters · filed 2026-08-13 | $7.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.65M 10-Q · filed 2026-05-15 | $3.58M derived: sum of 2 quarters · filed 2026-05-15 | $5.77M derived: sum of 3 quarters · filed 2026-05-15 | $8.27M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.13M derived: sum of 2 quarters · filed 2026-03-31 | $6.62M derived: sum of 3 quarters · filed 2026-03-31 | $8.92M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.19M 10-Q · filed 2025-11-13 | $4.69M derived: sum of 2 quarters · filed 2025-11-13 | $6.99M 10-Q · filed 2025-11-13 | $9.73M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.50M 10-Q · filed 2025-08-07 | $4.80M 10-Q · filed 2025-08-07 | $7.53M derived: sum of 3 quarters · filed 2025-08-07 | $11.05M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-06 | $5.04M derived: sum of 2 quarters · filed 2025-05-06 | $8.55M derived: sum of 3 quarters · filed 2025-05-06 | $12.23M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $6.25M derived: sum of 2 quarters · filed 2025-03-28 | $9.93M derived: sum of 3 quarters · filed 2025-03-28 | $13.54M 10-K · filed 2025-03-28 |
| 2023-09-30 | $3.52M 10-Q · filed 2024-11-07 | $7.19M derived: sum of 2 quarters · filed 2024-11-07 | $10.81M 10-Q · filed 2024-11-07 | $14.31M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.67M 10-Q · filed 2024-08-08 | $7.29M 10-Q · filed 2024-08-08 | $10.79M derived: sum of 3 quarters · filed 2024-08-08 | $14.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.61M 10-Q · filed 2024-05-14 | $7.12M derived: sum of 2 quarters · filed 2024-05-14 | $10.70M derived: sum of 3 quarters · filed 2024-05-14 | $14.54M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $7.09M derived: sum of 2 quarters · filed 2024-03-26 | $10.93M derived: sum of 3 quarters · filed 2024-03-26 | $14.56M 10-K · filed 2024-03-26 |
| 2022-09-30 | $3.59M 10-Q · filed 2023-11-07 | $7.43M derived: sum of 2 quarters · filed 2023-11-07 | $11.06M 10-Q · filed 2023-11-07 | $14.87M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $3.84M 10-Q · filed 2023-08-01 | $7.47M 10-Q · filed 2023-08-01 | $11.28M derived: sum of 3 quarters · filed 2023-08-01 | $15.65M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | $3.63M 10-Q · filed 2023-05-11 | $7.44M derived: sum of 2 quarters · filed 2023-05-11 | $11.81M derived: sum of 3 quarters · filed 2023-05-11 | $24.11M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $8.18M derived: sum of 2 quarters · filed 2023-03-23 | $20.47M derived: sum of 3 quarters · filed 2023-03-23 | $25.12M 10-K · filed 2023-03-23 |
| 2021-09-30 | $4.37M 10-Q · filed 2022-11-04 | $16.66M derived: sum of 2 quarters · filed 2022-11-04 | $21.31M 10-Q · filed 2022-11-04 | $24.33M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $12.30M 10-Q · filed 2022-08-09 | $16.94M 10-Q · filed 2022-08-09 | $19.96M derived: sum of 3 quarters · filed 2022-08-09 | $19.96M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.64M 10-Q · filed 2022-05-05 | $7.67M derived: sum of 2 quarters · filed 2022-05-05 | $7.67M derived: sum of 3 quarters · filed 2022-05-05 | $7.67M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.02M derived: sum of 2 quarters · filed 2022-02-28 | $3.02M derived: sum of 3 quarters · filed 2022-02-28 | $3.02M 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |